Our vision is to be the accepted PAIONeer in sedation and anesthesia; helping advance patient care.
Plans for further development of remimazolam for use in ICU sedation in the future are based on PAIONs expectation that the market for ICU sedation will present an attractive business opportunity. Based on available information from 2012 published in Critical Care Medicine which estimates average days of care in ICUs per year in the U.S., and journal articles published in the Intensive Care Medicine in 2012, which records, among others, the volume of ICU admissions per year and the number of total adult beds in various countries in the EU, PAION estimates that there are approximately 14 million ICU patient days requiring ICU sedation in the U.S. and EU combined per year. PAION expects this number to increase in the years to come, driven by demand from the aging population in both regions. PAION believes that such development, in turn, will foster demand for safer agents such as remimazolam, given the fact that elderly patients are much more likely to suffer from systemic health problems.
Internationally renowned anesthesiologists have repeatedly confirmed to PAION that ICU sedation bears an attractive market potential. However, development would be associated with the highest risk of side effects given the treatment of severely ill patients. For this reason, initially development in general anesthesia has priority for PAION. Development for ICU sedation requires additional funds.
Another field of high clinical need is pediatric use, which is a development requirement for both the EU and U.S. after the respective first approval.